Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001674324-25-000005·5AM Ventures V, L.P.
Schedule 13D ownership disclosure
Entrada Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 29384C108
Event date: 2025-11-14
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- 5AM Ventures V, L.P.Reported CIK 0001674324
Shares: 2,963,066.00 · Class: 7.8%
- 5AM Partners V, LLCReported CIK 0001791889
Shares: 2,963,066.00 · Class: 7.8%
- 5AM Opportunities I, L.P.Reported CIK 0001753000
Shares: 1,093,313.00 · Class: 2.9%
- 5AM Opportunities I (GP), LLCReported CIK 0001790778
Shares: 0.00 · Class: 2.9%
- Andrew J. SchwabReported CIK 0001598549
Shares: 4,056,379.00 · Class: 10.6%
- Kush ParmarReported CIK 0001664281
Shares: 4,123,849.00 · Class: 10.8%
- Scott M. RocklageReported CIK 0001219014
Shares: 2,963,066.00 · Class: 7.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001674324-25-000005
- Form type
- SCHEDULE 13D/A
- Filer
- 5AM Ventures V, L.P.
- CIK
- CIK 1674324
- Filed
- Nov 18, 2025
- Reporting period
- Nov 14, 2025
- Description
- Schedule 13D beneficial ownership